Basic Science Pathology

CNS Tumors

CNS Tumors

What You'll Learn

  • Most common brain tumor overall = metastasis; most common primary malignant brain tumor = glioblastoma (IDH-wildtype, grade 4); most common primary brain tumor (benign + malignant) = meningioma
  • Most common pediatric brain tumor = pilocytic astrocytoma (grade 1, cerebellar, BRAF fusion, excellent prognosis); most common malignant pediatric brain tumor = medulloblastoma
  • 2021 WHO CNS5 classification integrates molecular markers into tumor diagnosis — key classification-defining markers include IDH mutation status, 1p/19q codeletion, H3 K27-altered status, CDKN2A/B, TERT/EGFR/+7/−10, BRAF, and INI1/SMARCB1. MGMT promoter methylation is a key predictive marker for temozolomide response in glioblastoma but is NOT itself a WHO CNS5 classification-defining marker.
  • IDH mutation = better prognosis in diffuse gliomas; IDH-wildtype diffuse astrocytic tumor in adults is classified as glioblastoma regardless of histologic grade if molecular criteria are met
  • 1p/19q codeletion defines oligodendroglioma and predicts chemosensitivity (PCV regimen); MGMT promoter methylation predicts temozolomide response in glioblastoma
  • Hemorrhagic metastases mnemonic “MR CT”: Melanoma, Renal cell carcinoma, Choriocarcinoma, Thyroid — gray-white junction predilection
  • Genetic syndromes: NF1 → optic glioma; NF2 → bilateral vestibular schwannomas + meningiomas; VHL → hemangioblastoma; TSC → SEGA
  • Pseudopalisading necrosis + microvascular proliferation = glioblastoma; psammoma bodies = meningioma; Rosenthal fibers = pilocytic astrocytoma; Homer Wright rosettes = medulloblastoma
HighYield Pearls
  • WHO 2021 = molecular > histology: integrated molecular-histologic diagnosis — IDH, 1p/19q, H3 K27-altered (includes K27M and non-K27M mechanisms in diffuse midline glioma), CDKN2A/B, TERT/EGFR/+7−10, BRAF, and INI1/SMARCB1 drive classification, not microscope alone. MGMT methylation is predictive (TMZ response) rather than classification-defining.
  • CDKN2A/B homozygous deletion in IDH-mutant astrocytoma → grade 4 even without necrosis or microvascular proliferation; IDH-WT diffuse astrocytic tumor + TERT promoter mutation OR EGFR amplification OR +7/−10 → glioblastoma grade 4 regardless of histology
  • Oligodendroglioma requires BOTH IDH-mutant AND 1p/19q codeletion (ATRX retained); 1p/19q codeletion predicts chemosensitivity to PCV; frontal predominance, fried-egg cells, chicken-wire vasculature
  • Medulloblastoma 4 molecular groups: WNT (best prognosis, β-catenin nuclear, monosomy 6) > SHH (PTCH1/SUFU; TP53-WT better than TP53-mut) > Group 4 (most common) > Group 3 (MYC amp, worst); all get craniospinal RT + chemo
  • Ependymoma molecular subgroups: supratentorial ZFTA (RELA) fusion (worse) vs YAP1 fusion; posterior fossa Group A (high methylation, infants, worse) vs Group B (older, better); perivascular pseudorosettes + true ependymal rosettes
  • AT/RT = SMARCB1 (INI1) loss on IHC — pediatric, rhabdoid cells, highly aggressive; germline INI1 = rhabdoid predisposition syndrome; ETMR = LIN28A+ with C19MC alteration (infantile)
  • Pilocytic astrocytoma: KIAA1549-BRAF fusion (NOT V600E); cerebellar cyst + enhancing mural nodule; Rosenthal fibers + eosinophilic granular bodies; grade 1, excellent prognosis. PXA, ganglioglioma, papillary craniopharyngioma = BRAF V600E
  • NF2-related schwannomatosis (merlin/22q) → bilateral vestibular schwannomas + meningiomas + ependymomas; meningioma brain invasion alone OR atypical histologic features (including necrosis) upgrades to grade 2; grade 3 (anaplastic) requires frank anaplasia, very high mitotic activity, OR molecular criteria (TERT promoter mutation or CDKN2A/B homozygous deletion)
  • Hemorrhagic mets mnemonic “MR CT”: Melanoma, RCC, Choriocarcinoma, Thyroid (+ lung) — gray-white junction; PCNSL = periventricular, homogeneously enhancing, restricted diffusion, CD20+ large B-cell, HD-MTX
  • Bifocal pineal + suprasellar mass = synchronous germinomas; germinoma is PLAP+/OCT3/4+ and radiosensitive; NGGCTs use serum/CSF AFP (yolk sac) and β-hCG (choriocarcinoma) markers
🔍 Quick ReferenceHistology · Molecular · Imaging / location
Histology / immunohistochemistry
  • Pseudopalisading necrosis + microvascular proliferationGlioblastoma (astrocytoma grade 4, IDH-wildtype)
  • Fried-egg cells + chicken-wire vasculatureOligodendroglioma
  • Perivascular pseudorosettes (radial tumor cells around vessel) + true ependymal rosettesEpendymoma
  • Rosenthal fibers + eosinophilic granular bodies (EGB)Pilocytic astrocytoma (also PXA, ganglioglioma)
  • Homer Wright pseudorosettes + small blue round cellsMedulloblastoma
  • Rhabdoid cells with eccentric nuclei + INI1/SMARCB1 loss on IHCAT/RT (atypical teratoid/rhabdoid tumor)
  • Psammoma bodies + whorls + spindle/syncytial cells + EMA+Meningioma
  • Antoni A (Verocay bodies — palisading nuclei around acellular zone) + Antoni B (loose myxoid) + S100+Schwannoma
  • Schwann cells + axons + fibroblasts + mast cells (admixed)Neurofibroma (plexiform variant pathognomonic for NF1)
  • Stromal cells with foamy/vacuolated cytoplasm + rich capillary network + inhibin+Hemangioblastoma
  • Wet keratin nodules + “machine oil” cyst fluidAdamantinomatous craniopharyngioma
  • Lymphocyte-rich infiltrate + PLAP+ + OCT3/4+ large cellsGerminoma
  • CD20+ large B-cell perivascular infiltratePCNSL
  • Reticulin loss (vs normal acinar pattern) + monomorphic cellsPituitary adenoma
  • Brachyury (T)+ physaliphorous (bubbly) cellsChordoma
  • Floating neurons in mucin pools + cortical bubbly nodulesDNET (dysembryoplastic neuroepithelial tumor)
  • Pleomorphic + xanthomatous (lipid-laden) cells + reticulin + EGBPXA (pleomorphic xanthoastrocytoma)
Molecular markers
  • IDH-wildtype + TERT promoter mutation / EGFR amplification / +7/−10Glioblastoma grade 4 (regardless of histology)
  • CDKN2A/B homozygous deletion (in IDH-mutant astrocytoma)Grade 4 upgrade even without histologic features
  • IDH-mutant + 1p/19q codeletion + ATRX-retained (both required)Oligodendroglioma (PCV-chemosensitive)
  • MGMT promoter methylationTemozolomide response in glioblastoma
  • H3K27M / H3 K27-alteredDiffuse midline glioma, grade 4 (DIPG, thalamus, spinal cord)
  • KIAA1549-BRAF fusionPilocytic astrocytoma (NOT V600E)
  • BRAF V600EPXA, ganglioglioma, papillary craniopharyngioma (adamantinomatous = NOT V600E)
  • ZFTA (RELA) fusionSupratentorial ependymoma (worse) vs YAP1 fusion (better)
  • WNT-activated (nuclear β-catenin, monosomy 6)Medulloblastoma WNT (best prognosis); MYC amplificationGroup 3 (worst); PTCH1/SUFUSHH
  • SMARCB1 (INI1) lossAT/RT; germline = rhabdoid predisposition syndrome
  • LIN28A+ with C19MC alterationETMR (embryonal tumor with multilayered rosettes)
  • NF2 / merlin (22q) lossSchwannoma, meningioma, ependymoma
  • VHL (3p) inactivationHemangioblastoma (cerebellum + spinal) + RCC + pheo
  • AFP elevationYolk sac tumor; β-hCG elevationChoriocarcinoma (NGGCTs)
Imaging / location / clinical
  • Cystic cerebellar mass with enhancing mural nodule (child)Pilocytic astrocytoma
  • Cystic mass with enhancing mural nodule (adult, cerebellum/spinal)Hemangioblastoma (VHL; polycythemia from EPO)
  • Midline posterior fossa mass in child + hydrocephalusMedulloblastoma
  • 4th ventricle mass in child / spinal cord mass in adultEpendymoma
  • Butterfly lesion crossing corpus callosumGlioblastoma (or PCNSL)
  • Extra-axial dural-based mass + dural tail + intense homogeneous enhancementMeningioma
  • Bilateral CN VIII (cerebellopontine angle) massesNF2 vestibular schwannomas
  • Calcified suprasellar mass with cysts (child)Adamantinomatous craniopharyngioma
  • Periventricular homogeneously enhancing mass + restricted diffusion (immunocompromised)PCNSL
  • Multiple gray-white junction lesionsBrain metastases (lung, breast, melanoma, RCC, colon)
  • Bifocal pineal + suprasellar enhancing massSynchronous germinomas
  • Clival or sacral midline destructive massChordoma (notochordal remnant; brachyury+)
  • Superficial temporal cystic mass + epilepsy (young adult)PXA or ganglioglioma
  • Drug-resistant focal epilepsy + cortical bubbly multinodular lesionDNET
  • Olfactory groove mass with intracranial + sinonasal extensionEsthesioneuroblastoma
  • Frontal lobe tumor with calcifications (adult)Oligodendroglioma
  • Cardiac myxomas + spotty pigmentation + pigmented schwannomaCarney complex
🔒

Continue reading — sign in

The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.